Clinical Analysis Of 39 Cases Of Malignant Ovarian Tumors After Fertility-preserving Treatment

Objective: To explore the fetation effect factors of malignant ovarian tumors after fertility-preserving treatment.Methods: A retrospective clinical analysis was done on 10 patients with malignant epithelia tumors, 13 patients with borderline ovarian tumors,14 patients with ovarian malignant germ cell tumors and 2 patients with sexual cord stromal cell tumors who had undergone fertility-preserving management in the past 10 years. 12 patients underwent unilateral cystectomy(UC),20 patients underwent unilateral salping–oophorectomy(USO), 7 patients under- went USO,omentectomy and retroperitoneal sampling or pelvic cavity lymp- hadenectomy. 13 patients received PC(Cyclophosphamide, Cisplatin) regimen, 4 patients received BVP (Bleomycin, Vinblastin, Cisplatin) regimen, 9 patients received BEP (Bleomycin, Etoposide, Cisplatin) regimen. No chemotherapy was given to 13 patients. The average follow-up time was 48 months.Results: Thirty-eight among 39 patients have been alive up to now(97.1%). 33 patients had normal mensteuation. Sixteen patients among 34 patients who wanted to get pregnant had successful deliveries. Statistics show no significant difference in the pregnancy rate between two groups: UC and USO group, but the median pregnancy time after USO was more than in those treated with UC(P<0.05). Statistics show significant difference in the pregnancy rate and median pregnancy time between Chemotherapy group and the non-chemotherapy group(P<0.05).Conclusion: The management of fertility-saving surgery on patients with epithelial carcinomas is only indicated for low-stage(stageⅠ), high-grade(G1); No risk factors in patients with advanced BOT, the fertility-preserving is a safe option; For patients with ovarian malignant germ cell tumors, whatever the stagings are, fertility-preserving surgery is a safe option; Standard chemotherapy was the important prognosis factor for MOGCT and MOSCST. The median pregnancy time after USO was more than in those treated with UC if there no risk factors for recurrence. Ovary function impairment may occur in patients treated by ovarectomy followed by chemotherapy.